/

Sociétés

Or

Non vérifié

Orca Bio

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueOncologieSanté

25 communiqués de presse

Voir tous les communiqués de presse

17/09/2026

Oncologie

Santé

Biologie

Médecine - Divers

Biotechnologie

Industrie

Orca Bio Announces the Publication of TREGZI™ Long-Term Overall Survival Data in Transplantation and Cellular Therapy

Source

Émetteur

1.00

0

01/09/2026

Événements

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

Orca Bio to Present Clinical Data on TREGZI™ and Its Clinical Pipeline at the 14th Annual Meeting of the Society of Hematologic Oncology

Source

Émetteur

1.00

0

30/06/2026

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies

Source

Émetteur

1.00

0

15/06/2026

Industrie

Biotechnologie

Santé Publique

Santé

Oncologie

Orca Bio Adds East Coast Manufacturing Capacity and Triples West Coast Manufacturing Workforce Ahead of Potential Orca-T® Launch

Source

Émetteur

1.00

0

18/05/2026

Marché du travail

Oncologie

Santé

Biologie

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Orca Bio Appoints Bijan Nejadnik, M.D., as Chief Medical Officer

Source

Émetteur

1.00

0

28/04/2026

Industrie

Oncologie

Hygiène alimentaire

Santé

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Orca Bio Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies

Source

Émetteur

1.00

0

01/04/2026

Industrie

Biotechnologie

Industrie pharmaceutique

Santé

Oncologie

Orca Bio Announces FDA Review Extension of BLA for Orca-T for the Treatment of Hematologic Malignancies

Source

Émetteur

1.00

0

02/03/2026

Événements

Industrie

Oncologie

Santé

Biotechnologie

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Orca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annual Meeting of the EBMT

Source

Émetteur

1.00

0

05/02/2026

Biotechnologie

Industrie pharmaceutique

Santé

Oncologie

Industrie

Orca Bio Presents New Data at the 2026 Tandem Meetings of ASTCT® and CIBMTR® Reinforcing Orca-T® as a Durable, High-Precision Cell Therapy for Hematological Malignancies

Source

Émetteur

1.00

0

21/01/2026

Science

Biologie

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Médecine - Divers

Événements

Industrie

Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0